Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol administration; Placebo administration Clear all
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

NCT00879047
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Alcohol, Alcohol placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

NCT03372109
View directory record Official record
Conditions
Body Weight Changes
Interventions
Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

NCT00777062
View directory record Official record
Conditions
Cocaine Dependence, Alcohol Dependence
Interventions
VIVITROL (Naltrexone extended-release injectable suspension), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 21, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Xylitol, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

NCT03667846
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Topiramate, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

NCT01415531
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 54 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
75
States / cities
Phoenix, Arizona • Buena Park, California • Burbank, California + 58 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ibudilast, Placebo oral capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 9:54 PM EDT
Recruiting Phase 2Phase 3 Interventional

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

NCT07148843
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Alcohol Treatment With Lamotrigine

NCT04770493
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
16 Years to 24 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 21, 2026, 9:54 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
CMND-100
Drug
Lead sponsor
Clearmind Medicine Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

NCT02900352
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 21, 2026, 9:54 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 21, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Ibudilast for Treating Alcohol Use Disorder

NCT05414240
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcoholism
Interventions
Ibudilast, Medical management, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Kudzu Treatment for Alcohol Abuse

NCT01596231
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Kudzu, Placebo
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 21, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder

NCT06648655
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
TMP-301, Placebo
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

NCT07456852
View directory record Official record
Conditions
Malignant Digestive System Neoplasm
Interventions
Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

HA35 Acute Alcohol Study

NCT05025865
View directory record Official record
Conditions
Healthy Controls
Interventions
Sodium Hyaluronate, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

NCT00683800
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects

NCT00329407
View directory record Official record
Conditions
Alcoholism
Interventions
Topiramate (Topamax)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 21, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

NCT00563797
View directory record Official record
Conditions
Alcohol Dependence, Depression
Interventions
Mecamylamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 21, 2026, 9:54 PM EDT
Suspended Phase 1Phase 2 Interventional

Propranolol Treatment for Postoperative Chylothorax

NCT06833320
View directory record Official record
Conditions
Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions
Propranolol Hydrochloride, Placebo
Drug
Lead sponsor
June Wu
Other
Eligibility
7 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 9:54 PM EDT